Exanthematous drug eruptions. • «rashes». • Urticaria immediate reactions. • Delayed appearing exanthems with cell infiltration it is frequent. Therapy for exanthematous drug eruptions is supportive, involving the administration of oral antihistamines, topical steroids, and moisturizing. Morbilliform or exanthematous drug reaction (maculopapular drug eruption). Authoritative facts about the skin from DermNet New Zealand.

Author: Gajinn Vogar
Country: Turks & Caicos Islands
Language: English (Spanish)
Genre: Medical
Published (Last): 21 April 2017
Pages: 445
PDF File Size: 2.51 Mb
ePub File Size: 11.31 Mb
ISBN: 944-6-45334-433-1
Downloads: 69586
Price: Free* [*Free Regsitration Required]
Uploader: Gugal

What you should be alert for in the history The onset of a morbilliform eruption MDE; also known as exanthematous or maculopapular drug eruption typically occurs within 7 to 10 days after the initiation of the culprit drug.

The offending agent should be discontinued if possible. On the first occasion, a morbilliform rash usually adalh 1—2 weeks after starting the drug, but it may occur up to 1 week after stopping it. Powered By Decision Support in Medicine. No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC.

Morbilliform drug eruption is a form of allergic reaction. Self-skin examination New smartphone apps to check your skin Learn more Sponsored content. By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions.

Tests are not usually necessary if the cause has been identified and stopped, the rash is mild and the patient is well. Exanthem Drug eruptions Allergies explained Other websites: MDE is usually itchy.

Here Th 2 cells secrete interleukins 4, 13 and 5, which call eosinophils into the infiltrate, amongst other functions. Petechiae and macular purpura may be seen on the legs. However, histopathologic specimens that are performed in exanthematkus where a differential diagnosis exists will show epidermal changes, including small areas of spongiosis, which may or may not arise above areas of vacuolar change of the basal layer.


Which of the following best describes your experience with hand-foot-and-mouth disease? A few apoptotic keratinocytes and focal parakeratosis may be found. If you have any concerns with your skin or its treatment, see a dermatologist for advice. Oral corticosteroids at a dose of 0. Characteristic findings on physical examination Initially, there are erythematous blanching macules and papules, which may coalesce to form larger macules and plaques. Creams or lotions are useful for large surface areas.

In the dermis, there is a lymphocytic infiltrate with eosinophils. The diagnosis is made based on the typical clinical appearance in concert with an appropriate drug history and the absence of systemic involvement.

Antibiotics against group A Streptococcus should be administered.

Exanthematus, the rash will get worse before it ultimately gets better and resolves. Expected results of diagnostic studies The diagnosis is made based on the typical clinical appearance in concert with an appropriate drug history and the absence of systemic involvement. The target of attack may be drug, a metabolite of the drug, or a protein bonded to the drug. The calendar must extend back at least 2 weeks and up to one month. See the DermNet NZ bookstore.

Morbilliform Drug Eruptions (exanthematous drug eruption; maculopapular drug eruption, “drug rash”)

Many drugs can trigger this allergic reaction, but antibiotics are the most common group. Antihistamines are also useful when itch is severe. The patient should be made aware that pruritus and erythema may be severe. In the early phase, it may not be possible to clinically distinguish an uncomplicated morbilliform eruption from other more serious cutaneous adverse reactions SCAR.

On rechallenge with a drug that the patient has been sensitized to in the past, euption eruption may occur within 24 hours. The diagnosis of drug rash with eosinophilia and systemic symptoms DRESS should be ruled out in patients with a high fever, or with facial edema or lymphadenopathy.

The rash may be associated with a mild fever and itch. However, this is not always seen. On re-exposure to the causative or related drug, skin lesions appear within 1—3 days.


Morbilliform Drug Eruptions (exanthematous drug eruption; maculopapular drug eruption, “drug rash”)

Medical treatment Stop offending drug Mid- or high-potency topical steroids Antihistamines. If the reaction is mild, and the drug is essential and not replaceable, obtain a specialist opinion whether it is safe to continue the drug before doing so. What is the Cause of the Disease? Morbilliform drug eruption usually first appears on the trunk and then spreads to the limbs and neck. Prescribers must be vigilant. The face may be involved, but mucous membranes erkption typically spared.

Toxin-mediated erythemas, such as toxic shock syndrome and Strep toxic shock-like syndrome may present with an eruption that resembles MDE. A targetoid appearance to plaques and macules may be noted at this stage.

The presence of symptoms and signs that suggest GVHD, such as diarrhea, and liver function abnormalities should be looked for. An in-depth history and a drug chart may be required to assist in identification of the offending drug. Numerous other drugs have been reported to exxnthematous morbilliform drug eruptionsincluding herbal and natural therapies.

The eruption ezanthematous resolves within 7 to 14 days. Etiology A multitude of drugs have been implicated in MDE. Acute graft-versus host-disease GVHD. Type IV hypersensitivity has been subdivided into four groups, eanthematous on whether monocytes type IVaeosinophils type Exanthematoudor neutrophils type IVd are predominantly activated or whether there is T-cell-mediated apoptosis type IVc.

Exantjematous pain is a feature, as opposed to itch that accompanies MDE. Further investigations will depend on clinical features, progress of the patient, and the results of the initial tests.

Approach to the patient with a suspected drug eruption. There is a higher risk of all drug eruptions in the HIV-positive population and in women.